Northwest Biotherapeutics: Rodman & Renshaw Global Investments Conference (Northwest Biotherapeutics) - Sep 10, 2014 - "Completed multi-center Phase I / II trial with 36 patients"; "Showed positive efficacy signal and good safety (no toxicity)"; "
P1/2 data • Oncology • Prostate Cancer
|